Small molecule · Inhibitor of KAT6A (MOZ, MYST3) (KAT6A), KAT6B (MORF, MOZ2, MYST4) (KAT6B) and KAT7 (HBO1, MYST2) (KAT7) · developed by IDEAYA Biosciences
IDE574 is an orally bioavailable small molecule that inhibits the histone acetyltransferases KAT6A, KAT6B and KAT7, reducing acetylation of histones and other nonhistone substrates. It is being studied in ER-positive, HER2-negative breast cancer, non-small cell lung cancer, castration-resistant prostate cancer and microsatellite stable colorectal carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07540572 | Phase 1 | Cancer | Recruiting | IDYA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Castration-resistant Prostate Cancer (CRPC)ER+, HER 2- Breast CancerMicrosatellite Stable (MSS) Colorectal CarcinomaNon-small Cell Lung Cancer (NSCLC)
See IDYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IDYA catalysts and pipeline →